SSR180711 is a drug that acts as a potent and selective partial agonist for the α7 subtype of neural nicotinic acetylcholine receptors.[1][2] In animal studies, it shows nootropic effects and may be useful in the treatment of schizophrenia.[3][4]
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C14H21BrN2O2 |
| Molar mass | 329.238 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
References
edit- ^ Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, et al. (January 2007). "SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia". Neuropsychopharmacology. 32 (1): 17–34. doi:10.1038/sj.npp.1301188. PMID 16936709.17-34&rft.date=2007-01&rft_id=info:doi/10.1038/sj.npp.1301188&rft_id=info:pmid/16936709&rft.aulast=Pichat&rft.aufirst=P&rft.au=Bergis, OE&rft.au=Terranova, JP&rft.au=Urani, A&rft.au=Duarte, C&rft.au=Santucci, V&rft.au=Gueudet, C&rft.au=Voltz, C&rft.au=Steinberg, R&rft.au=Stemmelin, J&rft.au=Oury-Donat, F&rft.au=Avenet, P&rft.au=Griebel, G&rft.au=Scatton, B&rft_id=https://doi.org/10.1038%2Fsj.npp.1301188&rfr_id=info:sid/en.wikipedia.org:SSR-180,711" class="Z3988">
- ^ Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S, et al. (January 2007). "SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile". Neuropsychopharmacology. 32 (1): 1–16. doi:10.1038/sj.npp.1301189. PMID 17019409.1-16&rft.date=2007-01&rft_id=info:doi/10.1038/sj.npp.1301189&rft_id=info:pmid/17019409&rft.aulast=Biton&rft.aufirst=B&rft.au=Bergis, OE&rft.au=Galli, F&rft.au=Nedelec, A&rft.au=Lochead, AW&rft.au=Jegham, S&rft.au=Godet, D&rft.au=Lanneau, C&rft.au=Santamaria, R&rft.au=Chesney, F&rft.au=Léonardon, J&rft.au=Granger, P&rft.au=Debono, MW&rft.au=Bohme, GA&rft.au=Sgard, F&rft.au=Besnard, F&rft.au=Graham, D&rft.au=Coste, A&rft.au=Oblin, A&rft.au=Curet, O&rft.au=Vigé, X&rft.au=Voltz, C&rft.au=Rouquier, L&rft.au=Souilhac, J&rft.au=Santucci, V&rft.au=Gueudet, C&rft.au=Françon, D&rft.au=Steinberg, R&rft.au=Griebel, G&rft.au=Oury-Donat, F&rft.au=George, P&rft.au=Avenet, P&rft.au=Scatton, B&rft_id=https://doi.org/10.1038%2Fsj.npp.1301189&rfr_id=info:sid/en.wikipedia.org:SSR-180,711" class="Z3988">
- ^ Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, et al. (January 2008). "Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711". Biological Psychiatry. 63 (1): 92–7. doi:10.1016/j.biopsych.2007.04.034. PMID 17601496.92-7&rft.date=2008-01&rft_id=info:doi/10.1016/j.biopsych.2007.04.034&rft_id=info:pmid/17601496&rft.aulast=Hashimoto&rft.aufirst=K&rft.au=Ishima, T&rft.au=Fujita, Y&rft.au=Matsuo, M&rft.au=Kobashi, T&rft.au=Takahagi, M&rft.au=Tsukada, H&rft.au=Iyo, M&rft_id=https://doi.org/10.1016%2Fj.biopsych.2007.04.034&rfr_id=info:sid/en.wikipedia.org:SSR-180,711" class="Z3988">
- ^ Barak S, Arad M, De Levie A, Black MD, Griebel G, Weiner I (June 2009). "Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia" (PDF). Neuropsychopharmacology. 34 (7): 1753–63. CiteSeerX 10.1.1.470.1879. doi:10.1038/npp.2008.232. PMID 19158670. S2CID 827363.1753-63&rft.date=2009-06&rft_id=https://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.470.1879#id-name=CiteSeerX&rft_id=https://api.semanticscholar.org/CorpusID:827363#id-name=S2CID&rft_id=info:pmid/19158670&rft_id=info:doi/10.1038/npp.2008.232&rft.aulast=Barak&rft.aufirst=S&rft.au=Arad, M&rft.au=De Levie, A&rft.au=Black, MD&rft.au=Griebel, G&rft.au=Weiner, I&rft_id=http://ggriebel.perso.worldonline.fr/Pub107.pdf&rfr_id=info:sid/en.wikipedia.org:SSR-180,711" class="Z3988">
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |